Medivir acquires specialty pharma BioPhausia in a cash and stock deal that values BioPhausia at SEK1.65 per share, or about SEK565M ($91M)

BioPhausia AB

Sweden / Small-Cap Biopharma (<$1 billion)

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Medivir AB

Sweden / Small-Cap Biopharma (<$1 billion)

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Completed

Sample

01/01/2009

announced

01/01/2009

completed